SOUTH SAN FRANCISCO, Calif., April 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, May 5, 2009 to discuss the Company’s first quarter 2009 results and provide a corporate update. Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer and senior vice president, and Robert De Jager, M.D., chief medical officer, will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). A press release for the first quarter ended March 31, 2009, will be released after markets close on May 5.
To participate in the live call by telephone, please dial 877-741-4240 from the U.S. or 719-325-4751 for international callers. In addition, the live conference call is being Webcast and can be accessed on the “Events” page of the “News & Events” section of the Company’s Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company’s Web site for 10 days.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company’s lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic 2 colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit
http://www.poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
CONTACT: Susan Neath of Burns McClellan, +1-212-213-0006,
sneath@burnsmc.com; or Jani Bergan of WeissComm Partners, +1-415-946-1064
jbergan@wcpglobal.com, both for Poniard Pharmaceuticals, Inc.
Web site: http://www.poniard.com/
